• If you are wondering whether Catalyst Pharmaceuticals' recent share price puts it at a bargain or a stretch, the following sections break that question down into clear valuation checks.
• The stock last closed at US$30.86, with returns of 4.8% over the past week, 25.0% over the past month, 33.3% year to date and 33.8% over the past year, which raises questions about how that performance lines up with underlying value.
• Recent headlines around Catalyst Pharmaceuticals have focused on its position in the pharmaceuticals and biotech space and investor interest in its portfolio and pipeline. This helps frame why the share price has been active and provides useful context before comparing those expectations with more formal valuation tools.
• Catalyst Pharmaceuticals currently has a valuation score of 3 out of 6, indicating that it screens as undervalued on half of the checks used. It is therefore worth walking through the standard valuation methods next and then looking at a more complete way to think about value by the end of the article.

Approach 1: Catalyst Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth today by projecting its future cash flows and then discounting those back into present value using a required rate of return.

For Catalyst Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow stands at about $129.36 million. Analyst projections and subsequent extrapolations indicate free cash flow of $221 million in 2026 and a projected $340 million in 2030, all in $ terms.

Simply Wall St combines these yearly cash flow estimates, including the extrapolated values out to 2035, and discounts them back to today to arrive at an estimated intrinsic value of about $64.47 per share. Compared with the recent share price of $30.86, this DCF output implies the stock trades at a 52.1% discount to that intrinsic value estimate, which screens as undervalued on this model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Catalyst Pharmaceuticals is undervalued by 52.1%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Catalyst Pharmaceuticals Price vs Earnings

For profitable companies, the P/E ratio is a useful way to check how much you are paying for each dollar of earnings. This makes it an intuitive cross check against a DCF estimate. A higher P/E often reflects stronger growth expectations or lower perceived risk, while a lower P/E can point to more modest growth assumptions or higher uncertainty.

Catalyst Pharmaceuticals currently trades on a P/E of 17.6x. That sits close to the Biotechs industry average P/E of 17.2x, and below the peer group average of 29.3x, so the stock does not screen as expensive against these broad benchmarks. However, simple comparisons like these do not adjust for company specific factors.

Simply Wall St’s Fair Ratio for Catalyst Pharmaceuticals is 15.0x. This is a proprietary P/E estimate that aims to reflect what might be reasonable for the stock given its earnings growth profile, industry, profit margins, market cap and identified risks. Because it incorporates these company specific features, the Fair Ratio can be a more tailored guide than raw industry or peer averages. With the current P/E of 17.6x sitting above the Fair Ratio of 15.0x, the stock screens as overvalued on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Catalyst Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as your own story for Catalyst Pharmaceuticals that connects what you believe about its products, competitive risks and rare disease opportunities to a set of revenue, earnings and margin forecasts and, ultimately, to a fair value that you can easily compare with the current price.

On Simply Wall St’s Community page, Narratives are presented as an accessible tool used by millions of investors. You can either start from the analyst consensus view, which currently implies a fair value of US$34.29 per share with price targets that range from US$31.00 on the cautious side to US$40.00 on the optimistic side, or adjust the underlying assumptions if you think, for example, that FIRDAPSE concentration, FYCOMPA generic pressure or AGAMREE uptake will play out differently.

Because Narratives update automatically when new information, such as earnings releases, legal developments or clinical updates, is reflected in the underlying forecasts, they help you keep a clear link between your thesis on Catalyst Pharmaceuticals, the numbers that thesis implies and whether you see the stock as priced above or below your own view of fair value at any point in time.

Do you think there's more to the story for Catalyst Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.